Cantor Fitzgerald analyst William Tanner views TherapeuticsMD's disclosure of label negotiations with the FDA regarding TX-004 as a "tacit sign that the drug will be approved." The FDA action date is May 29 "so such an activity would be expected were the Agency prepared to issue a positive decision, in our experience," Tanner told investors yesterday in a research note. He cautions investors from viewing as probable an approval with a label that does not contain the estrogen class black box warning. However, given the drug's "tortuous development path," he believes any approval is a "clear positive." The analyst has an Overweight rating on TherapeuticsMD with a $28 price target.